Tirzepatide + Retatrutide
Also known as: Tirz + Reta, Dual-agonist + triple-agonist blend
Pre-mixed metabolic blend combining tirzepatide, a GIP/GLP-1 dual receptor agonist, with retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, both acting on incretin pathways to reduce appetite and improve glucose handling and weight. Tirzepatide is FDA-approved as a finished prescription drug (Mounjaro/Zepbound) but combining it with retatrutide is not an approved use; retatrutide remains investigational in Phase 3 (Eli Lilly TRIUMPH, NDA anticipated late 2026). This specific blend is not an approved product and has no published controlled human efficacy or safety data — any rationale is inferred from the separate agents, and combination-specific human data is lacking.
Common research uses
Pricing for Tirzepatide + Retatrutide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
No sellers for Tirzepatide + Retatrutide are indexed yet — we add vendors and their prices as we find them.
COAs for Tirzepatide + Retatrutide
2 third-party tests across 1 vendor. Each card links to the full report.
Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.